Amarin (AMRN) reported Q3 2024 financial results with total net revenue of $42.3 million, down 36% from $66.1 million in Q3 2023. The company maintains a strong cash position of $306 million. European VAZKEPA sales grew 19% sequentially, driven by Spain and UK markets. U.S. net product revenue was $30.6 million, while European and RoW revenues were $4.3 million and $6.9 million respectively. The company reported a net loss of $25.1 million or $0.06 per share. Operating expenses decreased 18% to $41.4 million due to cost optimization efforts.